Investigation of endothelial dysfunction and arterial stiffness in multisystem inflammatory syndrome in children

Murat Çiftel1 · Nurgül Ataş2 · Osman Yılmaz3

Received: 7 April 2021 / Revised: 25 May 2021 / Accepted: 27 May 2021 / Published online: 2 July 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021, corrected publication 2023

Abstract
Severe acute respiratory syndrome coronavirus 2 infection can result in multisystem inflammatory syndrome in children (MIS-C). MIS-C can lead to myocardial dysfunction, heart failure, and multiorgan failure; the primary finding is hyperinflammation. Endothelial dysfunction has not been evaluated in patients with MIS-C. We investigated endothelial dysfunction and arterial stiffness parameters in patients with MIS-C. The study included 38 pediatric patients (20 males and 18 females aged 4–17 years, mean age 8.89 years) with MIS-C. Thirty-eight age- and sex-matched healthy individuals were enrolled as the control group. Systolic and diastolic ventricular measurements and systolic and diastolic measurements of ascending aorta diameter were performed by M-mode echocardiography. Endothelial dysfunction was evaluated using flow-mediated dilation by measuring the brachial artery diameter with a high-resolution probe. The MIS-C group had lower flow-mediated dilation than did the controls. The MIS-C group had decreased aortic strain and aortic distensibility values and correlations between decreased flow-mediated dilation and reduced aortic strain, aortic distensibility, and reduced ejection fraction.

Conclusion: The results show that patients with MIS-C had endothelial dysfunction and arterial stiffness. Furthermore, the degree of endothelial dysfunction correlated with reduced ejection fractions.

What is Known:
- Endothelial dysfunction and arterial stiffness are unknown in patients with MIS-C.
- The effect of endothelial dysfunction and arterial stiffness on decreased cardiac function is unknown.

What is New:
- MIS-C patients have endothelial dysfunction and arterial stiffness.
- There is a link between left ventricular dysfunction and reduced endothelial dysfunction in patients with MIS-C.

Keywords Multisystem inflammatory syndrome in children · Flow-mediated dilation · Endothelial dysfunction · Arterial stiffness

Introduction
Coronavirus disease 2019 (COVID-19) is a viral respiratory disease characterized by hyperinflammation and cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in late 2019. SARS-CoV-2 is a single-stranded, positive-sense, enveloped RNA virus. It is thought to have originated in Wuhan City, Hubei Province, China [1]. After emerging in China, it spread rapidly worldwide, and the World Health Organization (WHO) declared COVID-19 a pandemic in March 2020 [2]. The first pediatric case of SARS-CoV-2 infection was reported in China [3]. Cardiovascular involvement is a common and important complication of COVID-19. Left heart failure and mitral insufficiency may
occur as results of the direct cytotoxic effect of the virus and the resulting cytokine storm [3, 4]. Endothelial damage, endothelial dysfunction, hyperinflammation, direct myocardial injury, increased oxygen demand, side effects of various treatments, and electrolyte imbalance play roles in cardiovascular dysfunction [4–6]. With the spread of COVID-19 among children, multisystem inflammatory syndrome in children (MIS-C) was identified as a post-infectious hyperinflammatory disease with symptoms similar to Kawasaki disease occurring 6–8 weeks after SARS-CoV-2 infection [7, 8]. MIS-C can lead to multiple organ failure, sometimes with cardiac involvement. Myocardial dysfunction, heart failure, and valvulitis are common presenting symptoms [8–10]. Endothelial dysfunction has been identified in the presence of inflammation [11, 12]. The endothelium plays roles in the regulation of endothelial vascular tone, vascular remodeling, immunity, inflammation, and platelet aggregation. Endothelial dysfunction may result from mechanical damage, bacterial infection, hyperinflammation, and autoantibodies [13]. Flow-mediated dilation (FMD) of the brachial artery enables noninvasive assessment of systemic endothelial function and the endothelium-dependent vasodilatory response of a vessel to elevations in blood flow-associated shear stress [14]. Endothelial dysfunction is associated with arterial stiffness and atherosclerosis. COVID-19 causes arterial stiffness and early vascular aging [15, 16]. To our knowledge, endothelial dysfunction and arterial stiffness in MIS-C have not been studied. We investigated endothelial dysfunction and arterial stiffness and their correlations with the degree of cardiac involvement.

Materials and methods

Study population

This prospective study was approved by the hospital’s ethics committee. Informed consent was obtained from all participants. Patients diagnosed with MIS-C in the Sanliurfa Training and Research Hospital between September 2020 and March 2021 were included in the study. Clinical diagnoses of MIS-C were made according to the diagnostic criteria of the US Centers for Disease Control and Prevention (CDC) and the WHO. MIS-C was diagnosed based on the presence of fever, signs of hyperinflammation, and multiorgan involvement, as well as evidence of association with COVID-19 and clinically severe disease requiring hospitalization in patients aged < 21 years [8, 9]. Diagnosis, treatment, and follow-up of patients with MIS-C were carried out by a multidisciplinary team that comprised staff from the Pediatric Cardiology, Pediatric Rheumatology, and Pediatric Infectious Diseases departments. The MIS-C group included persons aged 4–17 years. The control group comprised patients in whom heart disease was excluded by physical examination, electrocardiography, and echocardiography. The exclusion criteria were obesity, smoking, hypertension, congenital or acquired heart disease, and chronic kidney failure. In addition, children aged < 4 years were excluded because of issues with image quality. No sedation was used for echocardiographic measurement. Individuals with technically insufficient echocardiographic images were excluded from the study.

Patients who were stable after the diagnosis of MIS-C underwent measurement in the pediatric cardiology clinic. Echocardiographic measurement of unstable patients was performed at the bedside in the intensive care unit. In the patient group, echocardiographic measurement was carried out before the initiation of treatments that could affect endothelial function (inotropic therapy, administration of intravenous immunoglobulin, systemic glucocorticoids, and anakinra). After routine echocardiographic imaging, systolic and diastolic M-mode measurement of the ascending aorta was performed to assess arterial stiffness. Brachial artery measurement was performed next to identify endothelial dysfunction using the FMD technique. For patients in the control group, measurement was performed in the pediatric cardiology clinic. The subjects’ height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured. SBP and DBP were measured from the right brachial artery with the subject in the supine position using a mercury pressure gauge prior to examination after ≥5-min rest. The body mass index was calculated by dividing the body weight (in kilograms) by the square of the height (in meters).

Echocardiographic examination

Two-dimensional, M-mode, pulsed, and color flow Doppler echocardiographic examinations (Vivid S60N, 3-MHz transducer; GE, Horten, Norway) were performed by a pediatric cardiologist. During echocardiography, one-lead electrocardiographic measurement of unstable patients was performed at the bedside in the intensive care unit. In the patient group, echocardiographic measurement was carried out before the initiation of treatments that could affect endothelial function (inotropic therapy, administration of intravenous immunoglobulin, systemic glucocorticoids, and anakinra). After routine echocardiographic imaging, systolic and diastolic M-mode measurement of the ascending aorta was performed to assess arterial stiffness. Brachial artery measurement was performed next to identify endothelial dysfunction using the FMD technique. For patients in the control group, measurement was performed in the pediatric cardiology clinic. The subjects’ height, weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured. SBP and DBP were measured from the right brachial artery with the subject in the supine position using a mercury pressure gauge prior to examination after ≥5-min rest. The body mass index was calculated by dividing the body weight (in kilograms) by the square of the height (in meters).
The diastolic aortic diameter (AoD) was measured from the area corresponding to the QRS peak on simultaneous electrocardiographic recordings (Fig. 1). The following formulae were used to assess arterial elasticity: pulse pressure (PP) = SBP − DBP, aortic strain (%) = [(AoS − AoD) ÷ AoD] × 100, and aortic distensibility = 2 × [AoS − AoD ÷ AoD] × PP [18].

**Flow-mediated dilation measurement**

The brachial artery diameter was measured in the antecubital fossa immediately before its branching using a Doppler ultrasound system with a high-resolution transducer (Vivid S60N, 12 MHz linear-array transducer; GE). For two-dimensional imaging, a segment with clearly identifiable anterior and posterior intimal faces was selected. The brachial artery diameter was measured three times, and the average was recorded as the basal diameter. Measurements of the brachial artery were taken at the end of diastole according to electrocardiography monitoring. The cuff of the blood pressure device was placed in the upper part of the right antecubital fossa to create current impulses in the brachial artery. After baseline measurements were recorded, the cuff pressure was increased to 50 mmHg above the SBP, and the cuff was held in this position for 5 min to allow complete interruption of arterial flow. Anterograde blood flow was cut, and ischemia was induced. Sixty seconds after the cuff was deflated, two-dimensional longitudinal images of the brachial artery were obtained. FMD values were calculated using the baseline and maximum diameters of the brachial artery. FMD was calculated as: FMD = 100 × (maximum diameter after hyperemia − baseline diameter ÷ baseline diameter) [18].

**Statistical analysis**

SPSS statistical software (version 15.0; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Values are medians or means ± standard deviations. Pearson’s chi-squared test was used to examine differences in sex distribution and to assess the normality of the data distribution; the Shapiro–Wilk test was used for all other variables. The nonparametric Mann–Whitney U test was performed for non-normally distributed variables. Spearman’s correlation analysis was conducted to evaluate correlations. P values < 0.05 were considered to indicate statistical significance.
Results

The study included 38 pediatric patients (20 males and 18 females, mean age 8.89 years) who were matched for age, body mass index, and sex with control subjects. The ejection fractions of 20 (52%) patients were <55%. No patient had a coronary artery aneurysm. However, dilatation of the coronary arteries (Z score 2–2.5) was detected in five (13%) patients. Five patients had severe, 7 patients had moderate, and 10 patients had mild mitral valve insufficiency. Overall, 58% of patients had mitral insufficiency. In addition, seven (18%) patients showed minimal pericardial effusion. Some patients with MIS-C required intensive care (20/38, 53%), intravenous immunoglobulin (38/38, 100%), anakinra (25/38, 66%), pulse steroid (16/38, 42%), and inotropic therapy (26/38, 68%). Some patients in the MIS-C group showed reverse transcription polymerase chain reaction test positivity (3/38, 8%), serological positivity for COVID-19 (37/38, 97%), and histories of COVID-19 contact (35/38, 92%).

The inflammatory marker values were as follows: white blood cell count, 2150–47,500/μL (mean 14,004/μL, reference range 37–38, 97%), and of COVID-19 contact (35/38, 92%).

The MIS-C and control groups had similar pulse pressure (38.13 ± 8.62 and 40.63 ± 3.67, respectively; p = 0.10), systolic aortic diameter (2.11 ± 0.21 and 2.21 ± 0.25, respectively; p = 0.66), and diastolic aortic diameter (1.91 ± 0.20 and 1.89 ± 0.24, respectively; p = 0.81). Compared with the control group, patients with MIS-C had significantly increased left ventricular end-diastolic and end-systolic diameters (both p < 0.05) and decreased ejection fractions (p < 0.01) compared with the control group. The clinical characteristics and echocardiographic findings are provided in Table 1.

The MIS-C and control groups had similar pulse pressure (38.13 ± 8.62 and 40.63 ± 3.67, respectively; p = 0.10), systolic aortic diameter (2.11 ± 0.21 and 2.21 ± 0.25, respectively; p = 0.66), and diastolic aortic diameter (1.91 ± 0.20 and 1.89 ± 0.24, respectively; p = 0.81). Compared with the control group, patients with MIS-C had decreased aortic strain (11.64 ± 5.30 vs. 17.07 ± 4.44; p < 0.01) and aortic distensibility (8.90 ± 4.30 vs. 13.91 ± 3.70; p < 0.01). Patients in the MIS-C group also had decreased brachial artery diameter change (0.29 ± 0.12 vs. 0.40 ± 0.13; p < 0.01) and FMD (9.20 ± 3.81 vs. 12.10 ± 3.80; p < 0.01) relative to the controls (Table 2). There was a weak correlation between FMD and aortic strain (r = 0.39, p < 0.05) and aortic distensibility (r = 0.42, p < 0.05). There was a positive correlation (r = 0.67, p < 0.01) between FMD and ejection fractions. In addition, there was a significant positive correlation (r = 0.81, p < 0.01) between FMD and reduced ejection fraction (below 55%). In the MIS-C group, the correlation between flow-mediated dilation and ejection fraction is given in Fig. 2.

Discussion

MIS-C affects the heart, lungs, kidneys, brain, skin, eyes, and gastrointestinal tract; however, its cause is unknown. SARS-CoV-2 infection is typically mild and often asymptomatic.

Table 1  Clinical characteristics and results of conventional echocardiography

|                          | MIS-C (38 patients) | Controls (38 subjects) | P value |
|--------------------------|---------------------|------------------------|---------|
| Age (years)              | 8.89±2.67           | 8.94±2.69              | 0.82    |
| BMI (kg/m²)              | 19.63±2.31          | 20.13±1.84             | 0.30    |
| SBP (mmHg)               | 99.60±14.7          | 108.92±6.27            | 0.001   |
| DBP (mmHg)               | 61.47±9.60          | 68.15±5.87             | 0.001   |
| IVSd (mm)                | 6.21±1.09           | 6.07±1.26              | 0.62    |
| LVIDd (mm)               | 43.07±5.32          | 40.42±5.29             | 0.03    |
| LVPWd (mm)               | 5.76±1.26           | 5.63±1.38              | 0.66    |
| IVSs (mm)                | 9.71±1.37           | 9.68±2.02              | 0.94    |
| LVIDs (mm)               | 27.73±4.79          | 25.28±3.74             | 0.01    |
| LVPWs (mm)               | 9.31±1.61           | 9.26±1.55              | 0.88    |
| EF                       | 54.78±15.10         | 66.94±4.41             | 0.001   |

BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, IVSd interventricular septal wall thickness diastolic, LVIDd left ventricular internal dimension diastolic, LVPWd left ventricular posterior wall thickness diastolic, IVSs interventricular septal wall thickness systolic, LVIDs left ventricular internal dimension systolic, LVPWs left ventricular posterior wall thickness systolic, EF ejection fraction. Data are expressed as mean ± standard deviation.
in children, but some children develop MIS-C after acquiring it. MIS-C is characterized by fever, hyperinflammation, and multiorgan involvement and typically occurs 6–8 weeks after COVID-19 onset. The symptoms of MIS-C are similar to those of toxic shock syndrome and Kawasaki disease [7, 8]. The majority of affected children show polymerase chain reaction negativity for SARS-CoV-2. Most patients have positive serology as a sign of previous COVID-19, suggesting that MIS-C is a result of the immune dysregulation that develops after COVID-19 [8, 19]. MIS-C was first reported in Italy as an increase in the incidence of Kawasaki-like disease [7]. Later, the CDC and WHO published a case definition for MIS-C associated with COVID-19 [20, 21]. In MIS-C, systolic and diastolic heart functions are often impaired. Even after the recovery of systolic heart function, diastolic heart function deterioration has been detected [22]. Most patients have elevated troponin I or brain natriuretic peptide levels, which are signs of cardiac damage [9, 10]. Hyperinflammation, complement activation, microvascular damage, and endothelial damage have been detected in patients with MIS-C [23, 24]. The known causes of endothelial dysfunction are hyperinflammation, microvascular damage, and endothelial damage [13]. Left ventricular myocardial dysfunction is the most common cardiac finding of MIS-C. Heart failure is linked to endothelial dysfunction [25].

The endothelium is critical for the maintenance of vascular balance. Endothelial dysfunction can be defined as impaired endothelial vasodilation as a result of decreased nitric oxide release, increased nitric oxide degradation, or increased release of vasoconstriction mediators [13]. FMD is used to noninvasively assess nitric oxide-dependent vasoactivity [13, 14, 23]. Endothelial dysfunction can be caused by mechanical forces, bacterial infection, inflammation, and autoantibodies in circulation [26]. SARS-CoV-2 enters host cells via the angiotensin-converting enzyme-2 receptor, which is found in the respiratory tract and endothelial cells [1, 27]. Endothelial dysfunction and arterial stiffness have been detected in patients with COVID-19. Endothelial dysfunction and impaired microcirculatory function significantly contribute to life-threatening complications of COVID-19, such as venous thromboembolic disease and multiple organ involvement [16, 28]. We found that FMD values were decreased, indicating endothelial dysfunction, in patients with MIS-C. In MIS-C, endothelial dysfunction may cause cardiovascular and other organ involvement. Endothelial dysfunction has been detected in heart failure [25].
We found a positive correlation between decreased ejection fractions and decreased FMD. Thus, treatments for endothe-
lial dysfunction (angiotensin-converting enzyme inhibitors, antioxidants, beta blockers, endothelial nitric oxide synthase
enhancers, and phosphodiesterase-5 inhibitors) may be an option [29]. However, further studies are needed.

MIS-C is characterized by hyperinflammation, and inflam-
lation plays an important role in arterial stiffness. Further-
more, endothelial dysfunction may lead to atherosclerosis and
artrial stiffness. Increased arterial stiffness is associated with
an increased risk of cardiovascular events, such as stroke [11,
12, 16]. Increased arterial stiffness also increases the load on
the heart—more effort is required to maintain the heart rate.
Over time, this increased workload can lead to left ventricular
hypertrophy and remodeling, resulting in heart failure. More-
over, it increases the afterload on the heart, leading to an increase
in cardiac workload and contributing to heart failure [15, 16].
We found decreased aortic strain and distensibility, indicating
increased arterial stiffness, in patients with MIS-C. Arterial
stiffness is linked to inflammation and endothelial dysfunc-
tion. Whether increased arterial stiffness causes cardiovascular
events in patients with MIS-C, however, remains unclear.

This study has several limitations. First, the patients were
not followed prospectively for the recording of cardiovascular
events. Thus, we could not determine whether endothelial
dysfunction or arterial stiffness is a determinant of cardio-
vascular events. Second, endothelial dysfunction and arterial
stiffness were not evaluated after recovery. Thus, we could
not determine whether these changes are permanent or occur
only in the acute phase of the disease. Third, the assessment
of endothelial dysfunction by FMD is subject to interob-
server variability. Although FMD measurements were made
within the first hour, intravenous fluids (colloids, crystal-
loids, and dextrose fluids) can alter endothelial function.

In conclusion, this study is the first in which endothelial dys-
function and arterial elasticity were investigated in patients with
MIS-C. We found endothelial dysfunction and impaired arterial
elasticity in these patients. Furthermore, the degree of endothelial
dysfunction correlated with arterial stiffness and reduced ejection
fractions. In patients with MIS-C, endothelial dysfunction
may be a precursor of multiorgan failure, and therapeutic
approaches for endothelial dysfunction may be beneficial. Com-
prehensive prospective studies of this topic are needed.

Abbreviations COVID-19, Coronavirus disease 2019; CDC, US
Centers for Disease Control and Prevention; DBP, Diastolic blood pres-
sure; FMD, Flow-mediated dilation; MIS, Multisystem inflammatory
syndrome in children; SARS-CoV-2, Severe acute respiratory syndrome
coronavirus 2; SBP, Systolic blood pressure; WHO, World Health
Organization

Authors’ contributions Murat Ciftel: idea of the study, research,
planning, data collection, writing, and statistical analysis. Nurgül Ataş:
article writing and data collection. Osman Yılmaz: article writing and
data collection.

Data Availability The datasets analyzed during the current study are
available from the corresponding author on reasonable request.

Code availability Not applicable.

Declarations

Ethics approval This study was approved by the Ethics Committee,
Harran University (approval number: 0206-2020).

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan
H, Lei CL, Hui DSC, du B, Li L, Zeng G, Yuen KY, Chen RC,
Tang CL, Wang T, Chen PY, Xiang J, Li SY, Jiang L, Liang
ZJ, Peng YX, Wei L, Liu Y, Yu HY, Peng P, Wang JM, Liu JY,
Chen Z, Li G, Zheng ZJ, Quo SQ, Luo J, Ye CJ, Zhu SY, Zhong
NS, China Medical Treatment Expert Group for Covid-19 (2020)
China Medical Treatment Expert Group for Covid-19. Clinical
Characteristics of Coronavirus Disease 2019 in China. N Engl J
Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032

2. World Health Organization (WHO). WHO Director-General’s
opening remarks at the media briefing on COVID-19: 11 March
2020. Published March 11, 2020. Accessed March 11, 2020.
https://www.who.int/dg/speeches/detail/who-director-gener-
al-s-opening-remarks-at-the-media-briefing-on-covid-19-%2D%2D-
2D-11-march-2020

3. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J et al (2020)
A familial cluster of pneumonia associated with the 2019 novel
coronavirus indicating person-to-person transmission: a study of
a family cluster. Lancet 395:514–523. https://doi.org/10.1016/
S0140-6736(20)30154-9

4. Tezer H, Bedir DT (2020) Novel coronavirus disease (COVID-19)
in children. Turk J Med Sci 50:592–603. https://doi.org/10.3906/
sag-2004-174

5. Bansal M (2020) Cardiovascular disease and COVID-19. Diabetes
Metab Syndr 14:247–250. https://doi.org/10.1016/j.dsx.2020.03.
013

6. Xiong TY, Redwood S, Prendergast B, Chen M (2020) Coronavi-
ruses and the cardiovascular system: acute and long-term implica-
tions. Eur Heart J 41:1798–1800. https://doi.org/10.1093/eurhe
art/ezaa231

7. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuf-
freda M (2020) An outbreak of severe Kawasaki-like disease at
the Italian epicentre of the SARS-CoV-2 epidemic: an observa-
tional cohort study. Lancet 395:1771–1778. https://doi.org/10.1016/
S0140-6736(20)31103-X

8. Belhadjer Z, Météo M, Bajolle F, Khraiche D, Legendre A,
Abakka S, Auriau J, Grimaud M, Oualha M, Beghetto M, Wacker
J, Ovaert C, Hascoet S, Selegny M, Malekzadeh-Milani S, Mal-
tret A, Bosser G, Giroux N, Bonnemains L, Bordet J, Di Filippo
S, Mauran P, Falcon-Eicher S, Thambo JB, Lefort B, Moceri P,
Houyel L, Renolleau S, Bonnet D (2020) Acute heart failure in
multisystem inflammatory syndrome in children in the context of
global SARS-CoV-2 pandemic. Circulation 142:429–436. https://
doi.org/10.1161/CIRCULATIONAHA.120.048360
9. Alsaidi T, Tremoulet AH, Burns JC, Saidi A, Dionne A, Lang SM, Newburger JW, de Ferranti S, Friedman KG (2021) Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation. 143:78–88. https://doi.org/10.1161/CIRCULATIONAHA.120.049836

10. Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, Schnuriger A, Lorrot M, Guedj R, Ducou le Pointe H (2020) Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. Radiology 297:E283–E288. https://doi.org/10.1148/radiol.2020202288

11. Yang X, Chang Y, Wei W (2016) Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediat Inflamm 2016:6813016–6813019. https://doi.org/10.1155/2016/6813016

12. Zhang J, Tecson KM, McCullough PA (2020) Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med 21(315):–319. https://doi.org/10.31083/j.rcm.2020.03.126

13. Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P (2018 Mar) Endothelial cell metabolism in health and disease. Trends Cell Biol 28(3):224–236. https://doi.org/10.1016/j.tcb.2017.10.010

14. Raitakari OT, Celermajer DS (2000 Nov) Flow-mediated dilation. Br J Clin Pharmacol 50(5):397–404. https://doi.org/10.1046/j.1365-2125.2000.00277.x

15. Safar ME (2018 Feb) Arterial stiffness as a risk factor for clinical hypertension. Nat Rev Cardiol 15(2):97–105. https://doi.org/10.1038/nrcardio.2017.155

16. Green SJ (2020) Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect 22:149–150. https://doi.org/10.1016/j.micinf.2020.05.006

17. Çiftel M, Turan O, Simşek A, Kardelen F, Akçurin G, Ertuğ H (2014) Assessment of atrial electromechanical delay in children with acute rheumatic fever. Cardiol Young 24:27–32. https://doi.org/10.1016/j.tcb.2017.09.016

18. Çiftel M, Ertuğ H, Parlak M, Akçurin G, Kardelen F (2014) Investigation of endothelial dysfunction and arterial stiffness with diastolic dysfunction in diabetic children with type 1 diabetes mellitus and the association with diastolic dysfunction. Diab Vasc Dis Res 11:19–25. https://doi.org/10.1177/1479164113508564

19. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinho KM, Jaggii P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM, Maddux AB, Havalad V, Ransingham S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG (2020) Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 383:334–346. https://doi.org/10.1056/NEJMoa2021680

20. Centers for Disease Control and Prevention. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). May 29, 2020. https://www.cdc.gov/mis-c/hcp/. Accessed June 13, 2020.

21. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Scientific Brief. May 13, 2020. https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19

22. Matsubara D, Kaufman HL, Wang Y, Calderon-Anysora R, Nadaraj S, Elias MD, White TJ, Torowicz DL, Yubpu P, Giglia TM, Hogarty AN, Rossano JW, Quarterman MD, Banerjee A (2020) Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol 76:1947–1961. https://doi.org/10.1016/j.jacc.2020.08.056

23. Fox SE, Lameira FS, Rinker EB, Vander Heide RS (2020) Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19. Ann Intern Med 173:1025–1027. https://doi.org/10.1097/01.imo.0000632577.1038/ncardio.2017.155

24. Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE et al (2020) Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 4:6051–6063. https://doi.org/10.1182/bloodadvances.2020003471

25. Zuchti C, Trito I, Carlucio E, Mattei C, Cattadori G, Ambrosio G (2020) Role of endothelial dysfunction in heart failure. Heart Fail Rev 25:21–30. https://doi.org/10.1007/s10741-019-09881-3

26. Leask RL, Jain N, Butany J (2003) Endothelium and valvular diseases of the heart. Microsc Res Tech 60:129–137. https://doi.org/10.1002/jmri.100251

27. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G (2015) Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol 7:719–741. https://doi.org/10.4330/wjc.v7.i11.719

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.